Chris Webber

2.5k total citations
42 papers, 742 citations indexed

About

Chris Webber is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Chris Webber has authored 42 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Epidemiology, 14 papers in Microbiology and 7 papers in Infectious Diseases. Recurrent topics in Chris Webber's work include Pneumonia and Respiratory Infections (28 papers), Bacterial Infections and Vaccines (14 papers) and Respiratory viral infections research (13 papers). Chris Webber is often cited by papers focused on Pneumonia and Respiratory Infections (28 papers), Bacterial Infections and Vaccines (14 papers) and Respiratory viral infections research (13 papers). Chris Webber collaborates with scholars based in United States, United Kingdom and Netherlands. Chris Webber's co-authors include Marc J. M. Bonten, William C. Gruber, Daniel A. Scott, Susanne M. Huijts, Scott D. Patterson, Michael W. Pride, Beate Schmöele-Thoma, Jungsil Ro, Kathrin U. Jansen and Michael A. Patton and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Chris Webber

42 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris Webber United States 16 586 163 97 91 48 42 742
Diana Hu United States 12 448 0.8× 181 1.1× 76 0.8× 145 1.6× 11 0.2× 15 822
Martin van Cleeff United States 7 398 0.7× 92 0.6× 115 1.2× 28 0.3× 9 0.2× 9 512
Wendy C. S. Ho Hong Kong 15 361 0.6× 68 0.4× 63 0.6× 123 1.4× 49 1.0× 37 573
Howard D. Strickler United States 13 259 0.4× 19 0.1× 75 0.8× 244 2.7× 30 0.6× 23 653
M. Bartolomé Spain 12 432 0.7× 23 0.1× 42 0.4× 70 0.8× 10 0.2× 19 739
Wujun Jiang China 13 328 0.6× 99 0.6× 113 1.2× 70 0.8× 33 0.7× 51 542
Jason K. H. Lee Canada 11 419 0.7× 44 0.3× 135 1.4× 49 0.5× 8 0.2× 23 559
R. J. A. Diepersloot Netherlands 13 296 0.5× 29 0.2× 138 1.4× 47 0.5× 6 0.1× 16 591
Ayman Yosry Egypt 15 500 0.9× 28 0.2× 44 0.5× 99 1.1× 80 1.7× 60 782
M Diomandé Ivory Coast 10 417 0.7× 20 0.1× 388 4.0× 17 0.2× 17 0.4× 27 762

Countries citing papers authored by Chris Webber

Since Specialization
Citations

This map shows the geographic impact of Chris Webber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Webber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Webber more than expected).

Fields of papers citing papers by Chris Webber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Webber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Webber. The network helps show where Chris Webber may publish in the future.

Co-authorship network of co-authors of Chris Webber

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Webber. A scholar is included among the top collaborators of Chris Webber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Webber. Chris Webber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remich, Shon, Nicholas Kitchin, James T. Peterson, et al.. (2023). A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years. The Journal of Infectious Diseases. 229(2). 367–375. 9 indexed citations
2.
Bouguermouh, Salim, Kumar Ilangovan, Michael W. Pride, et al.. (2023). A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age. Vaccine. 41(50). 7548–7559. 9 indexed citations
3.
4.
Lawrence, Jody, Nicholas Kitchin, Annaliesa S. Anderson, et al.. (2021). Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50–85 years. Vaccine. 39(40). 5991–6003. 7 indexed citations
5.
Borja-Tabora, Charissa, Paula Peyrani, Chris Webber, et al.. (2020). A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases. 20(1). 426–426. 10 indexed citations
6.
Inoue, Megumi, Charles Knirsch, Michael W. Pride, et al.. (2019). A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine. 37(19). 2600–2607. 5 indexed citations
7.
Juergens, Christine, James Trammel, Yasuko Shoji, et al.. (2018). Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Human Vaccines & Immunotherapeutics. 14(8). 1948–1956. 4 indexed citations
8.
Gessner, Bradford D., Qin Jiang, Cornelis H. van Werkhoven, et al.. (2018). A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 37(38). 5777–5787. 44 indexed citations
9.
Serra, Lidia, et al.. (2018). A Review of Meningococcal Disease and Vaccination Recommendations for Travelers. Infectious Diseases and Therapy. 7(2). 219–234. 9 indexed citations
10.
Serra, Lidia, Laura J. York, Paul Balmer, & Chris Webber. (2018). Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents. Journal of Adolescent Health. 63(3). 269–279. 6 indexed citations
11.
Suaya, Jose A, Qin Jiang, Daniel A. Scott, et al.. (2018). Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 36(11). 1477–1483. 38 indexed citations
12.
Istúriz, Raúl, John M. McLaughlin, Vincenza Snow, et al.. (2017). Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age. Expert Review of Vaccines. 17(1). 45–55. 12 indexed citations
13.
Webber, Chris, Michael A. Patton, Scott D. Patterson, et al.. (2017). Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 35(9). 1266–1272. 22 indexed citations
14.
Blasi, Francesco, Murat Akova, Paolo Bonanni, et al.. (2016). Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. European Journal of Internal Medicine. 37. 13–18. 19 indexed citations
15.
Werkhoven, Cornelis H. van, Rosalind Hollingsworth, Susanne M. Huijts, et al.. (2016). Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine. 34(28). 3275–3282. 25 indexed citations
16.
Istúriz, Raúl, Beate Schmöele-Thoma, Daniel A. Scott, et al.. (2015). Pneumococcal conjugate vaccine use in adults. Expert Review of Vaccines. 15(3). 279–293. 15 indexed citations
17.
Huijts, Susanne M., Wim Boersma, D. E. Grobbee, et al.. (2014). Predicting pneumococcal community-acquired pneumonia in the emergency department. Clinical Microbiology and Infection. 20(12). 1316–1322. 7 indexed citations
18.
Zhang, Lei, Shannon P. Reidy, T. Nicholson, et al.. (2005). The Role of AEBP1 in Sex-Specific Diet-Induced Obesity. Molecular Medicine. 11(1-12). 39–47. 37 indexed citations
19.
Ro, Jungsil, et al.. (2001). Gene structure and expression of the mouse adipocyte enhancer-binding protein. Gene. 280(1-2). 123–133. 39 indexed citations
20.
Webber, Chris. (1987). Recent Amendments to the Canadian Criminal Code Respecting Computer Abuse Offenses. Santa Clara computer and high-technology law journal. 3(1). 165. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana Hu Breakdown of academic impact, for papers by Martin van Cleeff Breakdown of academic impact, for papers by Wendy C. S. Ho Breakdown of academic impact, for papers by Howard D. Strickler Breakdown of academic impact, for papers by M. Bartolomé Breakdown of academic impact, for papers by Wujun Jiang Breakdown of academic impact, for papers by Jason K. H. Lee Breakdown of academic impact, for papers by R. J. A. Diepersloot Breakdown of academic impact, for papers by Ayman Yosry Breakdown of academic impact, for papers by M Diomandé
Rankless by CCL
2026